Litigation Details for Spectrum Pharmaceuticals, Inc v. Sandoz Inc. (Fed. Cir. 2015)

Spectrum Pharmaceuticals, Inc v. Sandoz Inc. (Fed. Cir. 2015)

Docket		Date Filed	2015-03-03
Court	Court of Appeals for the Federal Circuit	Date Terminated
Cause		Assigned To
Jury Demand		Referred To
Patents	6,500,829
Link to Docket	External link to docket

Details for Spectrum Pharmaceuticals, Inc v. Sandoz Inc. (Fed. Cir. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-03-03				External link to document
2015-03-02	19		) Ruling that claims 1 and 2 of U.S. Patent No. 6,500,829 are invalid, that claims 5-9 are not infringed…#39;s ruling that claims 1 and 2 of U.S. Patent No. 6,500,829 are invalid for obviousness (Dkt. 368…Sandoz finding that claims 5-9 of U.S. Patent No. 6,500,829 would not be infringed by Sandoz's proposed…1) in ruling that claims 1 and 2 of U.S. Patent No. 6,500,829 are invalid for obviousness; and (2) in …in ruling that claims 5-9 of U.S. Patent No. 6,500,829 would not be infringed by Sandoz's proposed	External link to document

Litigation summary and analysis for: Spectrum Pharmaceuticals, Inc v. Sandoz Inc. (Fed. Cir. 2015)

Last updated: August 15, 2026

Spectrum Pharmaceuticals, Inc. v. Sandoz Inc., No. 15-1407, was a Hatch-Waxman patent dispute over generic levoleucovorin, marketed by Spectrum as Fusilev. The Federal Circuit affirmed the district court’s judgment that Spectrum’s asserted method-of-treatment patent claims were invalid for obviousness. The decision removed the principal patent obstacle to Sandoz’s ANDA product and materially weakened Spectrum’s exclusivity position for Fusilev.

Spectrum Pharmaceuticals v. Sandoz Patent Litigation: Case Summary, Holding, and Generic Entry Analysis

What was Spectrum Pharmaceuticals v. Sandoz about?

The case concerned Sandoz’s abbreviated new drug application for a generic version of Fusilev, Spectrum’s branded levoleucovorin calcium injection. Spectrum sued Sandoz under the Hatch-Waxman Act after receiving notice of Sandoz’s Paragraph IV certification.

Spectrum asserted U.S. Patent No. 8,598,219, which covered methods involving the administration of levoleucovorin in cancer treatment regimens. The litigation focused primarily on whether the asserted claims were obvious in view of earlier medical literature and clinical treatment protocols.

The Federal Circuit’s decision was reported as Spectrum Pharmaceuticals, Inc. v. Sandoz Inc., No. 15-1407, and is associated with the court’s published decision at 809 F.3d 1300 (Fed. Cir. 2016).

Which drug and patent were at issue?

Fusilev and levoleucovorin

Fusilev contains levoleucovorin, the pharmacologically active levo-isomer of leucovorin. The product was approved for use in connection with:

• Rescue after high-dose methotrexate therapy;
• Treatment of advanced metastatic colorectal cancer in combination with fluorouracil; and
• Certain folate-antagonist toxicity indications.

Fusilev was administered intravenously. Its commercial value depended on clinical use in oncology regimens where leucovorin or levoleucovorin was combined with fluorouracil and, in some treatment protocols, oxaliplatin.

Asserted patent

Item	Information
Patent holder	Spectrum Pharmaceuticals, Inc.
Asserted patent	U.S. Patent No. 8,598,219
Patent subject	Methods of treating cancer using levoleucovorin-based regimens
Defendant	Sandoz Inc.
Regulatory pathway	ANDA under Hatch-Waxman
Challenge	Paragraph IV certification
Federal Circuit docket	No. 15-1407
Federal Circuit result	Affirmed invalidity judgment
Principal issue	Obviousness

The asserted patent was a method-of-use patent rather than a patent directed solely to the chemical identity of levoleucovorin or to a manufacturing process.

What did the Federal Circuit decide?

The Federal Circuit affirmed the district court’s determination that the asserted claims were invalid as obvious under 35 U.S.C. § 103.

The court applied the conventional obviousness framework:

1. Determine the scope and content of the prior art.
2. Identify the differences between the prior art and the challenged claims.
3. Assess the level of ordinary skill in the relevant field.
4. Evaluate motivation to combine the references and the reasonable expectation of success.
5. Consider objective indicia of nonobviousness.

The court concluded that the prior art provided a sufficient basis for a skilled artisan to arrive at the claimed treatment regimen. The relevant treatment concepts, including the use of levoleucovorin in fluorouracil-based cancer therapy, were sufficiently disclosed or suggested by the prior art.

The Federal Circuit rejected Spectrum’s position that the claimed regimen represented a patentable departure from existing oncology practice. The court also found that the evidence of secondary considerations, including commercial success and industry acceptance, did not overcome the strong prima facie showing of obviousness.

Why did the patent fail the obviousness test?

Prior-art treatment regimens

The prior art disclosed the use of folinic acid, including levoleucovorin-related treatment concepts, in combination with fluorouracil for colorectal cancer. Earlier publications also described treatment approaches involving oxaliplatin and fluorouracil.

Spectrum argued that the specific sequence, dosing, or selection of levoleucovorin involved more than routine optimization. The court disagreed. It found that the claimed regimen was within the predictable scope of oncology treatment development.

Reasonable expectation of success

The court considered whether a skilled artisan would have expected the proposed combination to work, not whether the prior art guaranteed clinical success. The relevant standard did not require certainty. A reasonable expectation of success was sufficient.

The Federal Circuit determined that the prior art supplied the necessary expectation because the agents and treatment principles were already known in the relevant field. The combination did not depend on an unexplained or technically unpredictable interaction.

Secondary considerations

Spectrum relied on commercial success and related evidence to support nonobviousness. The court gave the evidence limited weight because Spectrum did not establish a strong nexus between the commercial performance of Fusilev and the claimed features of the patent.

Commercial sales can reflect factors other than the patented invention, including:

• FDA approval;
• Market demand for an injectable formulation;
• Supply shortages of alternative leucovorin products;
• Spectrum’s marketing and distribution strategy; and
• The clinical value of the active ingredient independent of the claimed method.

The Federal Circuit therefore treated the secondary evidence as insufficient to outweigh the prior-art showing.

What was the Hatch-Waxman and Paragraph IV significance?

Sandoz’s ANDA included a Paragraph IV certification asserting that the relevant patent was invalid, unenforceable, or would not be infringed by the proposed generic product.

Under 21 U.S.C. § 355(j)(5)(B)(iii), a Paragraph IV certification can trigger patent litigation before FDA approval. The lawsuit typically creates a 30-month stay of approval, subject to statutory exceptions and court action.

The case illustrates an important Hatch-Waxman distinction: a generic applicant can challenge a method-of-use patent even where the active ingredient itself is no longer protected by a valid composition-of-matter patent. The ANDA strategy can rely on a section viii statement, a Paragraph IV certification, or both, depending on the listed indications and labeling proposed by the generic applicant.

Once the asserted patent was held invalid and that result was affirmed, the patent could no longer support an injunction blocking Sandoz’s ANDA approval.

What was the litigation timeline?

Date or period	Event
2008	FDA approved Fusilev for specified oncology indications
2013	U.S. Patent No. 8,598,219 issued to Spectrum
Before Federal Circuit appeal	Spectrum sued Sandoz following Sandoz’s Paragraph IV certification
District court stage	Asserted claims were found invalid for obviousness
2015	Federal Circuit appeal docketed as No. 15-1407
2016	Federal Circuit affirmed the invalidity judgment
After affirmance	The asserted patent no longer blocked Sandoz based on the challenged claims

The precise commercial launch date for a Sandoz product would also depend on FDA approval, any remaining valid Orange Book-listed patents, pediatric exclusivity, regulatory exclusivity, and commercial launch decisions.

What was the Orange Book status of Fusilev?

Fusilev was an FDA-approved small-molecule injectable product, not a biologic. Its relevant intellectual-property issues were therefore governed by the Hatch-Waxman framework rather than the Biologics Price Competition and Innovation Act.

The Orange Book consequences were direct:

• Any listed method-of-use patent could be challenged through an ANDA certification.
• A Paragraph IV notice could trigger patent litigation.
• A judgment of invalidity eliminated the challenged patent as a basis for continued exclusivity.
• Remaining patents, if any, would need separate evaluation for scope, expiration, and enforceability.

The Federal Circuit decision did not create biosimilar risk because Fusilev is not a biologic. The competitive threat was ordinary generic entry through an ANDA.

What formulations were protected by Spectrum’s patent estate?

The litigation centered on treatment methods rather than a broad formulation monopoly. The patent at issue did not establish comprehensive protection over every levoleucovorin injectable formulation.

Potentially distinct patent categories for Fusilev included:

Patent category	Relevance to generic entry
Active ingredient or salt	Can block generic substitution if valid and unexpired
Injectable composition	May cover concentration, excipients, stability, or purity
Manufacturing process	May create process-specific barriers
Method of treatment	Can support Paragraph IV litigation
Labeling and indication	Can determine whether a generic must use a full or carve-out label

The invalidity ruling was most significant for the method-of-use layer. It did not automatically invalidate unrelated patents or eliminate every possible formulation or process claim associated with levoleucovorin.

How strong was Spectrum’s patent estate after the decision?

The estate was materially weaker after affirmance. The decision removed a patent that Spectrum had used to challenge a generic entrant and confirmed that the asserted treatment claims could not sustain exclusivity.

Strengths before the decision

Spectrum’s position had several commercial advantages:

• FDA-approved injectable product;
• Established oncology use;
• Patent coverage tied to clinically relevant treatment regimens;
• Ability to invoke the Hatch-Waxman litigation stay;
• Potential commercial leverage against generic applicants.

Weaknesses exposed by the decision

The litigation exposed four vulnerabilities:

1. The claimed regimen was close to established oncology protocols.
2. The prior art provided a credible motivation to combine known agents.
3. The treatment outcome was considered reasonably predictable.
4. Commercial success lacked a sufficiently strong nexus to the claimed invention.

For licensing or investment analysis, the ruling indicates that method-of-treatment claims covering predictable combinations of established oncology drugs face substantial obviousness risk.

Did the case involve a settlement agreement?

The Federal Circuit decision was an appellate merits decision affirming invalidity. It was not a settlement-based disposition.

No settlement agreement was necessary to resolve the appeal because the asserted patent claims were adjudicated invalid. Any separate commercial agreement between Spectrum and Sandoz would not alter the holding unless disclosed in a separate public filing or court order.

The absence of a settlement-based resolution increased the precedential value of the decision for assessing similar treatment-regimen patents.

What generic entry risks existed for Spectrum?

The principal risk was loss of blocking power against ANDA applicants seeking to market generic levoleucovorin.

Generic launch scenarios

Scenario	Effect
No remaining blocking patent	Generic entry after FDA approval and applicable regulatory exclusivity
Separate formulation patent remains valid	Entry may be delayed or product design may need modification
Method patent invalidated but label carve-out available	Generic may enter for non-patented indications
Valid patent settlement	Entry date depends on negotiated terms
Regulatory delay without patent barrier	FDA approval timing, not patent validity, controls launch

The decision also reduced Spectrum’s negotiating leverage with future ANDA filers. A generic company could cite the Federal Circuit holding when evaluating similar claims involving predictable combinations of known oncology agents.

How did the ruling affect revenue exposure?

The ruling put revenue associated with Fusilev at risk by removing a patent-based barrier to generic competition. The commercial impact depended on the number of remaining patents, FDA approval timing, generic capacity, reimbursement substitution, and hospital purchasing behavior.

Injectable oncology products can experience rapid price erosion after generic entry because hospitals, group purchasing organizations, and payers often favor lower-cost alternatives. The effect can be more pronounced where:

• The generic is therapeutically substitutable;
• The active ingredient is established;
• Multiple manufacturers enter;
• The product has limited formulation differentiation; and
• Prescribers do not need to change treatment protocols.

The decision did not itself establish the amount of lost revenue. It changed the legal exclusivity profile by eliminating one asserted patent as an enforceable barrier.

What manufacturing and intellectual-property barriers remained?

Generic manufacturers still had to satisfy FDA requirements for injectable products, including chemistry, manufacturing, and controls requirements. These regulatory hurdles are distinct from patent protection.

Potential non-patent barriers included:

• Sterility and aseptic manufacturing;
• Stability and shelf-life validation;
• Container-closure compatibility;
• Calcium salt handling;
• Batch consistency;
• FDA inspection readiness; and
• Commercial-scale supply reliability.

Those barriers can delay market entry but do not preserve patent exclusivity. A generic entrant that successfully obtains FDA approval can compete once applicable patent and regulatory restrictions expire or are removed.

What does the case mean for future oncology method patents?

The decision is adverse authority for claims that recite a predictable combination of known cancer drugs, known dosing concepts, and established clinical objectives.

A stronger patent position generally requires evidence of a technically unexpected result, such as:

• Unexpected efficacy;
• Unexpected toxicity reduction;
• A non-predictable dosing relationship;
• A previously unknown pharmacokinetic effect;
• A treatment population not suggested by the prior art; or
• A clinically meaningful result tied directly to the claimed limitations.

Commercial success alone is weak evidence when the product’s sales may be attributable to FDA approval, market demand, supply conditions, or the active ingredient rather than the claimed treatment method.

Key Takeaways

• Spectrum asserted U.S. Patent No. 8,598,219 against Sandoz’s generic levoleucovorin product.
• The Federal Circuit docket was No. 15-1407.
• The Federal Circuit affirmed invalidity based on obviousness.
• The prior art disclosed or suggested the relevant levoleucovorin and fluorouracil-based oncology treatment concepts.
• The court found a sufficient motivation to combine the prior art and a reasonable expectation of success.
• Commercial success and related secondary considerations did not overcome the obviousness case.
• The ruling removed a major Hatch-Waxman barrier to Sandoz’s ANDA product.
• Fusilev is a small-molecule drug, so biosimilar analysis does not apply.
• The decision did not automatically invalidate unrelated formulation, manufacturing, or other method patents.
• Generic entry remained subject to FDA approval and any surviving patent or regulatory restrictions.

FAQs About Spectrum Pharmaceuticals v. Sandoz

What was the main legal issue in Spectrum v. Sandoz?

The principal issue was whether Spectrum’s asserted levoleucovorin treatment claims were invalid as obvious under 35 U.S.C. § 103.

Did Sandoz win the patent case?

Yes. The Federal Circuit affirmed the district court’s judgment that the asserted patent claims were invalid, allowing Sandoz to overcome Spectrum’s principal patent-based challenge.

Was Fusilev protected by a biologic exclusivity framework?

No. Fusilev is a small-molecule injectable drug. Generic competition proceeds through the ANDA pathway, not the biosimilar pathway.

Did the ruling invalidate every Fusilev patent?

No. The decision concerned the asserted claims and did not automatically eliminate separate formulation, process, composition, or other method-of-use patents.

Why was Spectrum’s commercial-success evidence insufficient?

The court found that Spectrum did not establish a strong nexus between Fusilev’s commercial performance and the specific patented treatment features. Sales could reflect FDA approval, market demand, product availability, or the value of levoleucovorin itself.

References

1. Federal Circuit. (2016). Spectrum Pharmaceuticals, Inc. v. Sandoz Inc., No. 15-1407, 809 F.3d 1300 (Fed. Cir. 2016).

2. U.S. Food and Drug Administration. (2008). Fusilev approval letter and prescribing information. FDA.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.

4. United States Code. 35 U.S.C. § 103.

5. United States Code. 21 U.S.C. § 355(j).